Top

Published in:

01-10-2011 | Pharmacoeconomics: Original Research Article

Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

Authors: Steven Simoens, David Cassiman, Eline Picavet, Marc Dooms

Published in: Drugs & Therapy Perspectives | Issue 10/2011

Abstract

Hospital purchase prices substantially exceed compounding production costs in Belgium for selected orphan drugs that had low costs of research and development and market access procedures. As a result, healthcare payers seem to be paying too much for these orphan drugs and there are arguments for price reductions. Pharmacies can consider compounding, rather than purchasing, these orphan drugs.

Regulation (EC) no. 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official J Eur Commun 2000; L 18/1

Orphanet: the portal for rare diseases and orphan drugs [online]. Available from URL: http://www.orpha.net [Accessed 2011 May 9]

Denis A, Mergaert L, Fostier C, et al. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ 2010; 13(2): 295–301PubMedCrossRef

Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23(1): 36–42PubMedCrossRef

Regnstrom J, Koenig F, Aronsson B, et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 2010; 66(1): 39–48PubMedCrossRef

Boon W, Moors E. Exploring emerging technologies using metaphors: a study of orphan drugs and pharmacogenomics. Soc Sci Med 2008; 66(9): 1915–27PubMedCrossRef

Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: orphan designation status influences price. Appl Health Econ Health Policy 2011; 9(4): 1–5CrossRef

Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984; 34(10): 1324–30PubMedCrossRef

O’Neil M, Heckelman P, Koch C, et al. The Merck Index: an encyclopedia of chemicals, drugs and biologicals. Whitehouse Station (NJ): Merck Research Laboratories; 2006

10.

Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42(3): 518–25PubMedCrossRef

11.

Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981; 99(3): 467–72PubMedCrossRef

12.

Roy LP, Pollard AC. Cysteamine therapy for cystinosis. Lancet 1978; II (8092 Pt 1): 729–30CrossRef

13.

Tuchman M, Knopman DS, Shih VE. Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Arch Neurol 1990; 47(10): 1134–7PubMedCrossRef

14.

Hoogenraad TU, Van den Hamer CJ, Koevoet R, et al. Oral zinc in Wilson’s disease. Lancet 1978; 2(8102): 1262PubMedCrossRef

15.

Rinaldi A. Adopting an orphan. EMBO Rep 2005; 6(6): 507–10PubMedCrossRef

Title: Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs
Authors: Steven Simoens
David Cassiman
Eline Picavet
Marc Dooms
Publication date: 01-10-2011
Publisher: Springer International Publishing
Published in: Drugs & Therapy Perspectives / Issue 10/2011
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.2165/11601640-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2011

A variety of non-hormonal strategies may provide women with relief from vasomotor symptoms

Some antipsychotics and adjunctive antidepressants may minimize the risk of suicide in patients with schizophrenia

Consider the early use of antivirals when battling influenza infection in children

Eslicarbazepine acetate: a guide to its use as adjunctive therapy in partial-onset seizures

First reports of serious adverse drug reactions in recent weeks

Denosumab: a guide to its use in treating or preventing bone disease in various patient populations